The Patent Finder
BI

Biomerieux

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

340 patents currently held

19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
101
Ending by 2030
Dec 2026
Next term end
230
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Methods for Prognosis of Future Acute Renal Injury and Acute Renal Failure US 10,830,773
Cited by 29 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Ends Dec 2030 · High confidence
Also notable
Sample Handling Systems, Mass Spectrometers and Related Methods US 10,665,444
Cited by 13 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2039.
Ends Feb 2039 · High confidence
Also notable
Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure US 8,778,615
Cited by 40 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Ends Nov 2029 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Nov 21 to 28, 2026 · next Nov 21
  • 4 fees due Dec 4 to 23, 2026 · next Dec 4
  • 5 fees due Jan 2 to 30, 2027 · next Jan 2
  • 6 fees due Feb 6 to 27, 2027 · next Feb 6
  • 8 fees due Mar 3 to 29, 2027 · next Mar 3
  • 12 fees due Apr 6 to 29, 2027 · next Apr 6
  • 6 fees due May 3 to 19, 2027 · next May 3
  • 5 fees due Jul 14 to 28, 2027 · next Jul 14
  • 4 fees due Aug 6 to 20, 2027 · next Aug 6
  • 7 fees due Sep 1 to 30, 2027 · next Sep 1
  • 6 fees due Oct 7 to 26, 2027 · next Oct 7
  • 2 fees due Nov 10 to 19, 2027 · next Nov 10

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026
  • 9 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,578,978Carrier for Holding Test Samples
In force
 · High confidence
In forceHigh confidence
US 8,623,293Sealer for test sample devices
In force
 · High confidence
In forceHigh confidence
US 8,168,387Oligonucleotides, Use Thereof, Detecting Method and Kit for Diagnosing the Presence of H5 and N1 Genes of the Influenza a Virus
In force
 · High confidence
In forceHigh confidence
US 8,008,009Method for Prongf Assay for in Vitro Diagnosis of Cancer in Particular Breast, Thyroid or Lung Cancer and Therapeutic Use of Prongf
In force
 · High confidence
In forceHigh confidence
US 8,512,636Compact, integrated system for processing test samples
In force
 · High confidence
In forceHigh confidence
US 8,741,655Transport system for test sample carrier
In force
 · High confidence
In forceHigh confidence
US 8,067,209Method of Screening for the Presence of a Genetic Defect Associated with Deep Venous Thrombosis
In force
 · High confidence
In forceHigh confidence
US D684,275Specimen Container
In force
 · High confidence
In forceHigh confidence
US 8,298,761Nucleic Acid Sequences That Can Be Used as Primers and Probes in the Amplification and Detection of HSV DNA and Method for the Amplification and Detection of HSV DNA Using a Transcription Based Amplification
In force
 · High confidence
In forceHigh confidence
US 7,601,300Compact, Integrated System for Processing Test Samples
In force
 · High confidence
In forceHigh confidence
10 of 340 patents shown.
Pro members see all 340.
Pro members: see all 340 patents
Also on record, not counted in the 340: 19 patents in force now held by others · 170 patents ended · 39 applications pending · 142 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited